IVD Raw Materials Market Analysis & Forecast: 2026-2033

IVD Raw Materials Market Size and Share Analysis - Growth Trends and Forecasts (2026 - 2033)

The global IVD raw materials market value is at USD 34,281.6 Mn in 2026 and is forecast to reach a value of USD 50,790.6 Mn by 2033 at a CAGR of 5.8% between 2026 and 2033.

Key Takeaways

• Based on Product, the antibodies and antigens segment is expected to dominate the IVD raw materials market with 42% share in 2026, driving immunoassay and rapid diagnostic test development.
• Based on Technology, the immunochemistry segment is expected to hold 47.5% share in 2026, sustaining its role in routine clinical diagnostics worldwide.
• Based on End User, the diagnostic laboratories segment is projected to capture 53% share of the market in 2026, consuming most raw materials through expanding global testing networks.
• Based on Region, North America is set to lead the IVD raw materials market with 42.7% share in 2026. While, Asia Pacific is anticipated to be the fastest growing region.

Market Overview

The global IVD raw materials market is experiencing strong growth due to the high prevalence of infectious and chronic diseases, high demand for IVD testing and devices, growing awareness of early diagnosis and disease prevention, and rise in availability of advanced home care kits for cancer diagnostics. However, stringent regulations regarding product approvals and lower penetration of IVD devices are some major factors expected to hamper growth of the market.

Current Events and their Impacts on the IVD Raw Materials Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

IVD Raw Materials: Pricing, Cost Trends, and Assay Cost Contribution?

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights 

To learn more about this report, Download Free Sample

Which product segment dominates IVD raw material, antibodies and antigens?

In terms of product, the antibodies and antigens segment is expected to dominate the IVD raw materials market with 42% share in 2026. This is attributed to the increase in demand for IVD devices across the globe. Antigens and antibodies are the core raw materials used in the manufacture of IVD devices and reagents. The dominance is observed due to their indispensable role in immunoassays, rapid diagnostic tests and ELISA kits. They hold an ability to detect a wide range of disease, making consistent demand.

For instance, Leinco Technologies' purchase of BioClin's antibody clones makes its IVD raw materials portfolio stronger. The deal makes it easier for people to get important antibodies used in diagnostic tests for hormones like TSH, hCG, and FSH. This move strengthens antibodies and antigens as the most important product group in the IVD raw materials market.

How does immunochemistry establish dominance in IVD raw materials technology?

In terms of technology, the immunochemistry segment is expected to hold 47.5% share in 2026, owing to its widespread utilization in routine clinical diagnostics. The dependency on antibody-antigen interacts for accurate disease detection offers its dominance. The immunochemistry maintains a strong hold due to its established infrastructure, broad acceptance in laboratories globally, and cost-effectiveness.

For instance, in November 2025, CACLP 2026 focuses on immunochemistry raw materials for IVDs, showcasing reagents, consumables, and upstream parts. The China IVD Key Raw Materials & Parts Forum is part of the event. It includes companies from around the world, such as Roche and Thermo Fisher, that focus on new ideas, working together, and integrating the supply chain in the development of diagnostic manufacturing and immunochemistry reagents.

Why do diagnostic laboratories surge as leading end-users in IVD raw materials?

In terms of end user, the diagnostic laboratories segment is projected to capture 53% share of the market in 2026, driven by rising diagnostic scale, expansion in laboratory networks, and increasing reliance on standardized testing. They are the central hub for deploying immunoassays, and molecular diagnostics, boosting the IVD raw material market growth.

For instance, in April 2025, Tokuyama acquired JSR's IVD business, which includes immunoassay reagents, companion diagnostics, and the raw materials needed to make reagents. Companies like MBL and G&G Science are involved. This makes Tokuyama's healthcare division stronger by giving diagnostic labs more antigens, antibodies, and particle raw materials. It also helps precision medicine and cancer diagnostics move forward.

Regional Insights 

To learn more about this report, Download Free Sample

North America IVD Raw Materials Market Analysis & Trends

North America is expected to gain highest share of 42.70% in the IVD raw materials market in 2026 due to the rising incidence of chronic diseases and rapidly growing geriatric population in this region. For instance, in vitro diagnostics can detect diseases or other conditions, and can be used to monitor a person’s overall health to help cure, treat, or prevent diseases. As per the Centers for Disease Control and Prevention (CDC), chronic diseases, such as heart disease, cancer, and diabetes, are the leading causes of death and disability in the United States. Six in ten Americans live with at least one chronic disease.

For instance, in June 2025, Fujirebio bought Plasma Services Group in the US, which makes it a stronger supplier of important biological raw materials. The deal guarantees a steady supply of high-quality plasma and serum, which are needed for in vitro diagnostics and life sciences. This makes the global supply chain more reliable and helps diagnostic labs all over the world.

Asia Pacific IVD Raw Materials Market Analysis & Trends

Asia Pacific is also expected to witness robust growth in the global IVD raw materials market due to the increase in prevalence of chronic diseases and rapidly growing geriatric population in this region. For instance, two in every three senior citizens in India suffer from some chronic disease, according to the first Longitudinal Ageing Study in India (LASI) by the Union Ministry of Family and Health Welfare. This in turn is expected to increase demand for IVD raw materials in this region.

IVD Raw Materials Market Outlook Country-Wise

The U.S. IVD Raw Materials Market Trends

The U.S. IVD raw materials market is exceptionally competitive in 2026 because of the country's advanced healthcare system, high levels of research and development spending, the growing number of chronic and infectious diseases, and the widespread use of molecular diagnostics. Large biotech companies and innovation hubs keep the demand for antibodies, antigens, enzymes, and proteins high.

For instance, in June 2025, Applied DNA Sciences, which is based in New York, got a second order for its synthetic LineaDNA platform worth more than USD 600,000. A global IVD maker will get the bulk DNA for cancer tests, making LineaDNA an important raw material in the supply chain for diagnostic reagents.

China IVD Raw Materials Market Trends

China's IVD raw materials market has a highly competitive in 2026 because healthcare is growing quickly, the government is working on projects like Healthy China 2030, chronic and infectious diseases are becoming more common, and the biotech manufacturing capacity is growing. As more things are made locally, the need for antibodies, antigens, enzymes, and proteins rises.

For instance, in April 2025, At Medlab Asia & Asia Health 2025 in Kuala Lumpur, Beijing Hotgen Biotech showcased its newest immunoassay technologies. Chemiluminescence immunoassay solutions, portable UPT systems, and the C800 analyzer were some of the most important things. These new products focus on advanced reagents and consumables, which strengthens Hotgen's position as a leader in global IVD raw material and diagnostic solutions.

Market Report Scope 

Global IVD Raw Materials Market Drivers

High prevalence of chronic diseases across the world

High prevalence of chronic diseases across the world is expected to augment the global IVD raw materials market demand during the forecast period. Chronic diseases are the leading causes of disability and death among the elderly population worldwide. According to the World Health Organization (WHO), noncommunicable diseases (NCDs) kill 41 million people each year, equivalent to 71% of all deaths globally. Cardiovascular diseases account for most NCD deaths (17.9 million), followed by cancers (9.3 million), and diabetes (1.5 million). Over 77% of all NCD deaths are in low- and middle-income countries.

Technological advancements in IVD raw materials

Technological advancements in IVD raw materials are expected to boost the growth of the global IVD raw materials market during the forecast period. For instance, in November 2025, Fapon's Medica 2025 showcased features new IVD raw materials, such as advanced Alzheimer's blood testing biomarkers (p-tau, amyloid beta, GFAP, NfL, APOE4), recombinant calibrators, IgG blockers that don't come from animals, and LAMP solutions. These breakthroughs make diagnostic tests more sensitive, specific, and reliable, which is a big step forward in the field of in vitro diagnostics.

Global IVD Raw Materials Market Opportunities

Personalized Medicine Spurs Rising Demand for IVD Raw Materials

Increasing awareness and acceptance of personalized medicine is expected to offer significant growth opportunities for players in the global IVD raw materials market. For instance, the term precision medicine refers to the tailoring of diagnostics or therapeutics to individual patients based on their unique genetic and physiologic characteristics. The trend toward personalized medicine is driving demand for diagnostics. IVD can be used in precision medicine to identify patients who are likely to benefit from specific treatments or therapies.

Point-of-Care Diagnostics Drive Market Growth Opportunities

Increase in the use of point-of-care (POC) diagnostics is expected to provide significant growth opportunities for players in the global IVD raw materials market. The market is being driven by increased demand for quick diagnostic tests, which has prompted industry players to deliver POC solutions to decentralized regions. In March 2026, Co-Diagnostics expanded its distribution in South Asia to include Bangladesh, Pakistan, Nepal, and Sri Lanka. The deal helps to sell more of its CoSara PCR Pro point-of-care instrument and SARAGENE tests for infectious diseases. This strategic move makes it easier for people in the region to get quick molecular diagnostics, which fits with the global push for decentralized testing solutions.

Global IVD Raw Materials Market Trends

Rising Global Demand and Regulatory Compliance

The IVD raw materials market is growing in 2026 because of rising global demand and stricter regulatory compliance. This will ensure that diagnostic workflows continue without interruption, encourage innovation, and support industry growth in many healthcare areas around the world.

Growing Geriatric Population

Growing geriatric population across the globe is expected to propel the growth of the global IVD raw materials market. For instance, chronic diseases are the leading causes of disability and death among the elderly population worldwide. According to World Health Organization (WHO), by 2030, 1 in 6 people in the world will be aged 60 years or over, and by 2050, the world’s population of people aged 60 years and older will double (2.1 billion).

Analyst Opinion (Expert Opinion)

• Antibodies and antigens are the most commonly used in diagnostic tests, especially immunoassays and quick test kits. The growth of diagnostic laboratories and contract research organizations has led to more use of enzymes and proteins in molecular diagnostics and point-of-care testing. The Asia-Pacific region is seeing the fastest growth in adoption, driving by rising healthcare spending and there is more investment in biotechnology infrastructure.
• The industry is steadily growing, with North America staying on top because of established diagnostic networks. At the same time, Asia-Pacific is growing faster thanks to local manufacturing and government-backed healthcare programs. The market is not concentrated, which makes it easier for new companies to enter, especially in the areas of specialized reagents and biological buffers. At the same time, changing tariff structures and international trade policies are making supply chains more resilient.

Global IVD Raw Materials Market: Key Developments

• In March 2026, Solabia obtained SEQENS's Botanical Actives and IVD businesses in Limoges, France. The deal makes Solabia's diagnostics portfolio stronger and makes sure that raw materials and reagents for diagnostic labs keep being developed. SEQENS, on the other hand, will focus on pharmaceutical solutions and specialty ingredients. This deal has a direct effect on the European IVD supply chain.
• In March 2026, With the Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx kits, Integrated DNA Technologies got into the clinical diagnostics business. These IVD-grade reagents are based on proprietary Anchored Multiplex PCR chemistry. They standardize workflows, make results more accurate, and help with cancer testing. The launch shows that IDT is moving from making oligos to providing clinical-grade raw materials for diagnostics.

Market Segmentation

• Global IVD Raw Materials Market, By Product
  • Antibodies & Antigens
  • Enzymes
  • Proteins
  • Biological Buffers
  • Others
• Global IVD Raw Materials Market, By Technology
  • Clinical Chemistry
  • Immunochemistry
  • Molecular diagnostics
  • Others
• Global IVD Raw Materials Market, By End-User
  • Pharma, Biotech & MedTech Companies
  • Diagnostic Laboratories
  • Others
• Global IVD Raw Materials Market, By Region
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • North Africa
    • Central Africa
• Global IVD Raw Materials Market: Key Players
  • Aalto Bio Reagents
  • Fapon Biotech
  • Fujirebio
  • Merck KgaA
  • Hoffmann-La Roche
  • Thermo Fisher Scientific

Sources

Primary Research Interviews

• IVD Raw Material Manufacturers
• Antibodies, Antigens, and Enzyme Suppliers
• Diagnostic Reagent and Kit Manufacturers
• OEM/ODM Diagnostic Component Providers
• Molecular Diagnostic Raw Material Suppliers
• Clinical Laboratory Procurement Managers
• Regulatory and Quality Assurance Experts
• Others

Databases

• Bloomberg Terminal
• Thomson Reuters Eikon
• D&B Hoovers
• Others

Magazines

• IVD Technology Magazine
• Clinical Lab Products
• GenomeWeb
• Medical Product Outsourcing Magazine
• BioPharm International
• Others

Journals

• Clinical Chemistry
• Journal of Molecular Diagnostics
• Diagnostics Journal
• Clinica Chimica Acta
• Journal of Immunological Methods
• Others

Newspapers

• Financial Times
• The Wall Street Journal
• Reuters
• Bloomberg News
• The Economic Times
• Others

Associations

• Association for Diagnostics & Laboratory Medicine (ADLM)
• Medical Device Manufacturers Association (MDMA)
• American Clinical Laboratory Association (ACLA)
• European Diagnostic Manufacturers Association (EDMA) / MedTech Europe Diagnostics
• Clinical and Laboratory Standards Institute (CLSI)
• Others

Public Domain Sources

• U.S. Food and Drug Administration (FDA)
• Centers for Disease Control and Prevention (CDC)
• World Health Organization (WHO)
• European Commission – Public Health and Medical Devices
• National Institutes of Health (NIH)
• National Center for Biotechnology Information (NCBI)
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for the Last 8 Years

Definition: In vitro diagnostics can detect diseases or other conditions, and can be used to monitor a person’s overall health to help cure, treat, and/or prevent diseases. The core raw materials of in vitro diagnostic (IVD) reagents/kits include antibodies, antigens, enzymes, etc., which are important determinants of the quality and effectiveness of the reagents/kits.